高危结直肠腺瘤的危险因素及风险预测模型的构建与验证

摘要 目的：探讨高危结直肠腺瘤的影响因素,构建风险预测模型并验证。方法：回顾性分析2021年1月至2021年12月期间在江苏大学附属人民医院进行诊疗的1408例结直肠腺瘤患者的资料,根据病理特征分为高危结直肠腺瘤组（759例）和非高危结直肠腺瘤组（649例）。采用Logistic回归分析筛选高危结直肠腺瘤的独立危险因素并建立风险预测模型,并验证预测模型的应用效能。结果：Logistic回归分析结果显示,病灶部位为直肠、高血压、高脂血症、年龄≥53岁、吸烟是高危结直肠腺瘤的独立危险因素（P＜0.05）。基于以上因素建立预测高危结直肠腺瘤风险的列线图模型,经Hosmer-Lemeshow检验和受试者工作特征曲线（ROC）分析显示,该风险预测模型具有较好的拟合度和预测效能,可以用于高危腺瘤的风险预测。结论：病灶部位为直肠、高血压、高脂血症、年龄≥53岁、吸烟是高危结直肠腺瘤的独立危险因素,临床医生可尽早对高危患者进行预防性干预以减缓高危腺瘤的发生。     

Expression of p21ras-related protein in the plasma and tissue of patients with adenomas and carcinomas of the colon

Over-expression of p21 ras-related protein was determined in the plasma by immunoblotting and in the tissue by immuno-histochemistry in a cohort of patients undergoing colonoscopy. In the plasma samples, p21 ras over-expression was detected in: 9% (4/47) of normal controls; 21% (13/61) of individuals with normal colonoscopies but with a prior history of colonic neoplasia; 12% (4/33) of small adenoma patients, 29% (6/21) of large adenoma patients; 63% (5/8) of carcinoma-in-adenoma patients; 50% (2/4) of Dukes' A carcinoma patients; and 20% (2/10) of Dukes' B-D carcinoma patients. In the tissue samples, p21 ras over-expression was detected in: 25% (2/8) of small adenoma patients; 44% (4/9) of large adenoma patients; 100% (4/4) of carcinoma-in-adenoma patients; and 33% (1/3) of Dukes' B-C carcinoma patients. For matched plasma-tissue pairs, there was a statistically significant correlation for p21 ras over-expression (R = 0.47, p = 0.02).     

Recurrent gain-of-function USP8 mutations in Cushing's disease

Cushing''s disease, also known as adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas (PAs) that cause excess cortisol production, accounts for up to 85% of corticotrophin-dependent Cushing''s syndrome cases. However, the genetic alterations in this disease are unclear. Here, we performed whole-exome sequencing of DNA derived from 12 ACTH-secreting PAs and matched blood samples, which revealed three types of somatic mutations in a candidate gene, USP8 (encoding ubiquitin-specific protease 8), exclusively in exon 14 in 8 of 12 ACTH-secreting PAs. We further evaluated somatic USP8 mutations in additional 258 PAs by Sanger sequencing. Targeted sequencing further identified a total of 17 types of USP8 variants in 67 of 108 ACTH-secreting PAs (62.04%). However, none of these mutations was detected in other types of PAs (n = 150). These mutations aggregate within the 14-3-3 binding motif of USP8 and disrupt the interaction between USP8 and 14-3-3 protein, resulting in an elevated capacity to protect EGFR from lysosomal degradation. Accordingly, PAs with mutated USP8 display a higher incidence of EGFR expression, elevated EGFR protein abundance and mRNA expression levels of POMC, which encodes the precursor of ACTH. PAs with mutated USP8 are significantly smaller in size and have higher ACTH production than wild-type PAs. In surgically resected primary USP8-mutated tumor cells, USP8 knockdown or blocking EGFR effectively attenuates ACTH secretion. Taken together, somatic gain-of-function USP8 mutations are common and contribute to ACTH overproduction in Cushing''s disease. Inhibition of USP8 or EGFR is promising for treating USP8-mutated corticotrophin adenoma. Our study highlights the potentially functional mutated gene in Cushing''s disease and provides insights into the therapeutics of this disease.     

垂体瘤微环境免疫细胞浸润与肿瘤侵袭性的相关性研究

目的:探讨垂体瘤免疫微环境中免疫细胞浸润情况及其与垂体瘤侵袭性的相关性。方法:选取35例垂体瘤病理组织切片,通过免疫组化染色分析巨噬细胞、T细胞以及中性粒细胞的特异性标记蛋白CD68、CD4、CD8和MPO的表达情况。结合临床和影像学数据分析,分析生长激素腺瘤、泌乳素腺瘤和无功能腺瘤的侵袭性与免疫细胞浸润数量的相关性。结果:在15例生长激素腺瘤,10例泌乳素腺瘤和10例无功能性腺瘤患者中,侵袭性垂体瘤中有更多的巨噬细胞浸润(P分别为0.014,0.032和0.032)。侵袭性促生长激素腺瘤、泌乳素腺瘤和无功能性腺瘤巨噬细胞浸润数量均明显多于非侵袭性促生长激素腺瘤、泌乳素腺瘤和无功能性腺瘤(P0.05)。结论:在垂体腺瘤中,巨噬细胞是肿瘤免疫微环境的主体。巨噬细胞浸润可能促进垂体瘤的进展。     

Fine needle aspiration cytology of basal cell adenoma of the salivary gland: a cytohistological correlation study of 35 cases

B. Vicandi, J.A. Jiménez‐Heffernan, P. López‐Ferrer, P. González‐Peramato, M. Patrón and J.M. Viguer
Fine needle aspiration cytology of basal cell adenoma of the salivary gland: a cytohistological correlation study of 35 cases Objective: In order to evaluate the possibility of a specific cytological recognition of basal cell adenoma (BCA) we reviewed our experience with 35 histologically proven cases. Few series describing cytological features of BCA are available and diagnostic cytological criteria are not well established. Methods: This study was based on 41 cytology samples from 35 patients with BCA. Thirty‐five aspiration procedures were performed pre‐operatively and six on tumour recurrence. Nineteen of the 35 patients were men and 16 women. The mean age at diagnosis was 55 years old (range 24–92). The series includes one non‐representative case. Except for one tumour located in the upper lip, all of them involved the parotid gland. Results: Aspirates were cellular, showing groups with dense, homogeneous metachromatic stroma and single cells. Relevant features were the trident‐like configuration of groups, intimate relationship between neoplastic cells and stroma and cellular polymorphism. In approximately half of the cases a precise diagnosis was given. Most of the remaining tumours were diagnosed as benign but they were difficult to differentiate from pleomorphic adenoma. Regarding malignancy, there were two misdiagnoses of acinic cell carcinoma, due to high epithelial cellularity along with scarcity of stroma, and one case was considered to be suspicious of malignancy. Conclusion: BCA shows characteristic cytological features that allow a precise diagnosis. The main differential diagnosis is epithelial‐rich pleomorphic adenoma, while acinic cell carcinoma is a potential false positive.     

Management of adenomas and toxic multinodular goiters with Iodine 131

In accordance with all the guidelines of the various international scientific societies, treatment using radioiodine (RAI) of autonomous toxic adenomas and toxic multinodular goiters is highly recommended and its effectiveness its efficacy has now been widely demonstrated and established. RAI treatment is effective to normalise thyroid function, remove functional autonomy and reduce thyroid volume. According to published data on several thousand patients treated with RAI, the success rates ranges between 85% and 100%. Moreover, with more than 70 years of experience, this treatment does not present any particular risk for patients. However, as regards pregnancy, there are no absolute contra-indications to radioiodine treatment. To date, these results include a relatively high rate of hypothyroidism in the long term and approximately one patient out of five treated, will require thyroid hormone substitution. It would be more effective to harmonise and work up on dosimetric personalized models allowing the calculation of the effective dose to be delivered to the autonomous nodule to be treated while preserving the normal thyroid parenchyma in order to optimise the patient's outcome and to favor extensive euthyroidism.     

The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro

The aim of the work was to investigate the effects of somatostatin analogs acting selectively on sst1 (BIM-23926), sst2 (BIM-23120) and sst5 (BIM-23206) receptor subtypes on the viability of "clinically non-functioning" pituitary adenomas in vitro. The effects of native SST (SST-14), a SST/DA chimera (BIM-23A387) and a D(2)-dopamine receptor agonist bromocriptine (BC) were also examined. The study was performed on 10 surgically removed pituitary macroadenomas, diagnosed before surgery as "non-functioning". A part of each tumor was mechanically dispersed and digested with collagenase to isolate the tumoral cells. Another part of each tumor was fixed, embedded in paraffin and immunostained to reveal the pituitary hormones and SST receptor subtypes (sst1, sst2A, sst2B, sst3, sst4, sst5). The tumoral cell suspensions were incubated for 24 h with the substances mentioned above. The quantity of viable cells was estimated using the EZ4U system. The results were compared with the immunohistochemical evaluation of the hormonal profile of adenoma and the sst receptor subtype immunoreactivities present. The findings indicate that selective sst1, sst2 and sst5 receptors agonists, SST/DA chimera and D(2)-dopamine receptor agonist bromocriptine affect the viability of some, but not all, "clinically non-functioning" pituitary adenomas in vitro. The most effective was bromocriptine. The investigated somatostatin analogs including SST/DA chimera exerted roughly similar inhibitory effects. Further studies are needed to fully evaluate the potential usefulness of these compounds in the pharmacological treatment of "non-functioning" pituitary tumors.